Forestier F, Daffos F, Rainaut M, Toulemonde F
Centre de Diagnostic Prénatal et de Faetologie, Hôpital Notre-Dame-de-Bon-Secours, Paris.
J Gynecol Obstet Biol Reprod (Paris). 1987;16(8):981-6.
Using low molecular weight fractions of heparin (HBPM) can be at least potentially useful in pregnant women for certain indications. After animal studies had been carried out for toxic effects, one HBPM, CY216, which has been put on the market under the name of Fraxiparin, was studied to see whether it crosses the placenta in pregnant women by analysing fetal blood directly. Seven women who had fetal indications for terminating their pregnancies in the third trimester received a subcutaneous injection of 17,500 Choay units of Fraxiparin (0.7 ml). The haemostatic state was assessed in the mothers before the injection and three hours after it, and in the fetus approximately three hours after the injection into the mother. The fetal blood was taken in the uterus by direct aspiration using ultrasound guidance techniques. Anti Xa, anti IIa, and cephalin-kaolin time (TCK) were estimated. The anti Xa, anti IIa and the TCK were not changed in the 7 fetuses that were studied, 3 hours after the subcutaneous injection of a large dose of CY 216 although marked changes were noted in the mothers.
对于某些适应症，使用低分子量肝素片段（HBPM）对孕妇至少可能是有用的。在对动物进行了毒性作用研究之后，对一种名为CY216的HBPM进行了研究，该药物已以速碧林（Fraxiparin）的名称上市，通过直接分析胎儿血液来观察其是否会穿过孕妇的胎盘。七名在妊娠晚期有终止妊娠胎儿指征的妇女皮下注射了17,500乔雅单位的速碧林（0.7毫升）。在注射前和注射后三小时对母亲的止血状态进行评估，并在向母亲注射后约三小时对胎儿的止血状态进行评估。使用超声引导技术通过直接抽吸在子宫内采集胎儿血液。估计抗Xa、抗IIa和白陶土部分凝血活酶时间（TCK）。在皮下注射大剂量CY216三小时后，所研究的7名胎儿的抗Xa、抗IIa和TCK没有变化，尽管母亲体内出现了明显变化。
